electroCore reports Q1 EPS ($1.24), consensus ($1.00)

Reports Q1 revenue $ $2.78M, consensus $2.95M."We recorded revenue of $2.8M during the first quarter of 2023, an increase of 46% over the first quarter of 2022," stated Dan Goldberger, Chief Executive Officer of electroCore. "We made significant strides with our marketing and sales efforts for Truvaga, bringing in net sales of about $147,000 in the first full quarter since launching in December 2022. Furthermore, we are excited about the continued momentum and interest behind all our product offerings, including prescription gammaCore for certain medical conditions, TAC-STIM(TM) for human performance and Truvaga for consumer wellness."